Dianthus Therapeutics, Inc. (DNTH) stock
Close on Nov 11, 2026Market cap $4.99BP/E –Yield 0.00%
Dianthus Therapeutics, Inc. saw revenue fall 67.3% to $2.04M over fiscal 2025. At the latest close the market valued the company at $4.99B.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Sep 30, 2026
Valuation
- Market cap
- $4.99B
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 4.02
- Dividend yield
- 0.00%
- Free cash flow yield
- –
Fundamentals
- Revenue
- $2.04M
- Net income
- -$202.12M
- EPS, diluted
- -$3.99
- Book value per share
- $21.65
- Diluted shares
- 57M
Trading
- Next earnings
- Mar 8, 2027 (estimated, before the open)
- Previous close
- $88.81
- Open
- $89.05
- Day's range
- $87.97 – $90.45
- Volume
- 794,735
- Average volume (20 days)
- 943,329
- Index membership
- Russell 2000 (since Sep 2024), Russell 3000 (since Aug 2024)
- Beta (5 years)
- 1.44
- 52-week range
- $34.29 – $117.88
- RSI (14 days)
- 59.7
- Volatility (1 year)
- 60.6%
- Relative volume
- 0.93×
- WACC
- 12.1%
On 1 of our idea list: Most shorted (a warning list)
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2018, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | DNTH | S&P 500 | Difference | DNTH per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +8.4% | -2.4% | +10.8 pts | ||
| 3 months | -17.7% | -1.2% | −16.5 pts | ||
| Year to date | +116.7% | +12.3% | +104.4 pts | ||
| 1 year | +147.4% | +12.4% | +134.9 pts | ||
| 3 years | +676.5% | +78.8% | +597.7 pts | +98.0% | +21.4% |
| 5 years | -24.9% | +75.2% | −100.0 pts | -5.6% | +11.9% |
Eleven years at a glance
Fiscal years 2015 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Dianthus Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- News
- Results
- News
- Results
- Results
About Dianthus Therapeutics
Pharmaceutical Preparations
The company is a clinical-stage biotechnology firm dedicated to creating targeted therapies for individuals affected by severe autoimmune conditions. Its pipeline focuses on investigational candidates, led by claseprubart, an engineered monoclonal antibody that selectively inhibits active C1s complement protein, and DNTH212, a bifunctional fusion protein targeting BDCA2 and BAFF/APRIL. Through these biological agents, the enterprise targets disorders such as generalized Myasthenia Gravis, Chronic Inflammatory Demyelinating Polyneuropathy, and Multifocal Motor Neuropathy, with intended end users being patients suffering from complement-dependent and related neuroinflammatory disorders.
Company profile, executives and historyDianthus Therapeutics stock: common questions
What is Dianthus Therapeutics's stock price?
DNTH closed at $89.30 on Nov 11, 2026, up 0.55% on the day. Over the past 52 weeks it traded between $34.29 and $117.88.
What is Dianthus Therapeutics's market cap?
Dianthus Therapeutics was worth $4.99B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is DNTH's P/E ratio?
Dianthus Therapeutics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$3.99), so it has no meaningful P/E ratio.
How much revenue does Dianthus Therapeutics make?
Dianthus Therapeutics reported revenue of $2.04M for fiscal 2025, down 67.3% from a year earlier.
Does Dianthus Therapeutics pay a dividend?
No. Dianthus Therapeutics has not paid a cash dividend over the last twelve months.
When does Dianthus Therapeutics report earnings next?
Dianthus Therapeutics is expected to report Q4 FY2026 results on Mar 8, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has DNTH stock performed over the past year?
Including dividends, DNTH returned +147.4% over the past year, against +12.4% for the S&P 500.
How many DNTH shares are sold short?
9M shares were sold short at the latest FINRA report, 18.25% of the float, or 10.1 days of average trading volume.
Who are Dianthus Therapeutics's competitors?
Companies most similar to Dianthus Therapeutics by business, industry and size include RNAC, CNTB, UPB, CAMP, YARW.
See a number that looks wrong?